SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East shipping and energy-infrastructure threats are driving crude-oil supply concerns and attention to USO. Traders are split between expecting further gains if disruptions persist and anticipating a pullback if diplomacy or additional supply eases the risks; many also worry that elevated oil prices could pressure equities and inflation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure after HSBC warned that heavy borrowing needs and potentially slower AI-compute demand could challenge its growth and returns, sharpening traders concerns about debt, refinancing, and dilution amid a broader neocloud selloff. Bears warn of credit and business-model risks, while bulls point to contracted demand and continued AI infrastructure growth; some also cite Goldman Sachss more positive view and ARKs share purchases.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO slide and fresh lows are driving discussion, with traders pointing to continued lockup-related share supply and insider selling, as well as a TD Cowen price-target cut and concerns about growth and customer concentration. Bearish traders expect more pressure, while some bullish holders view the decline as an oversold buying opportunity and argue the companys AI-chip technology has long-term potential.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius has been caught in a sharp neocloud and AI-infrastructure selloff as traders debate whether heavy buildout spending can earn adequate returns and whether financing risksespecially at CoreWeavewill spread across the sector. The community is split between treating the rebound after the decline as an oversold bounce and expecting more downside, while some argue Nebius is better positioned than debt-heavier peers and that compute demand remains strong.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and limited firm customer commitments, with uncertainty around the proposed TVA deployment adding to execution concerns. Traders are split between viewing the selloff as an overreaction and seeing it as confirmation of risks facing NuScale and the broader nuclear sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent selloff, ahead of major megacap earnings, is driving QQQ discussion. Traders are divided over whether it marks a durable recovery or a relief rally that could fade, with AI investment and debt concerns and surging oil prices adding to caution.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces third-quarter earnings beat and raised 2026 guidance are driving attention, with traders also citing stronger orders. Many view the report as bullish, while others are cautious about whether the stock can hold its post-earnings strength amid muted or weakening price action.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat estimates, but traders are focused on the tightened full-year profit outlook rather than a larger guidance increase. The new buyback program is a positive offset for some, while others question why shares are falling despite the beat.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention ahead of its Q3 earnings report, with traders anticipating a beat and stronger guidance while citing major missile and counter-drone awards as signs of sustained defense demand. Optimism about a rebound competes with concerns that expectations are high and contract wins have not always translated into stronger share performance.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrops Q3 results beat expectations and management raised its full-year outlook, with a record backlog reinforcing the growth case. Traders are debating why shares remain under pressure despite the strong report, pointing to margin and cash-flow concerns and the possibility that the positive news was already priced in.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?

T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMDPR NewswireDALLAS, Sept. 15, 2026 DALLAS, Sept. 15, 2026 /PRNewswire/ -- Through an exclusive...

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of +20.00% and -3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD's Series A Preferred Stock Crosses Above 9.5% Yield Territory

In trading on Monday, shares of LifeMD Inc's 8.875% Series A Cumulative Perpetual Preferred Stock (Symbol: LFMDP) were yielding above the 9.5% mark based on its quarterly dividend (annualized to $2.2188), with shares changing hands as low as $22.91 on the day. As of last clos...

CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Hims & Hers Expands Integrated Health Access via Platform Expansion

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

Is CAH Becoming the Backbone of US Healthcare Infrastructure?

Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.

Bloomberg Businessweek Daily 5/18/2026

Today, Matt Schettenhelm, Bloomberg Intelligence Senior Litigation Analyst, breaks down a California's jury's rejection of Elon Musk's claim that Sam Altman betrayed OpenAI's original mission when it...

LifeMD (NASDAQ:LFMD) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

LifeMD (NASDAQ:LFMD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The business had...

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

LifeMD (LFMD) delivered earnings and revenue surprises of -42.86% and +3.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD Inc

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Costco Wholesale Corp

CVS Health Corp

GoodRx Holdings Inc

Structure Therapeutics Inc - ADR

Hims & Hers Health Inc

Lilly(Eli) & Co

Novo Nordisk A/S

Pfizer Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$LFMD Federated Hermes bought 2.5M shares last quarter, this quarter they bought another 1.5M. Seems they believe in LFMD and is now the biggest shareholder.

rolypoly101

$LFMD The pots a brewing any fucking day we gonna creep out of the sewers and fly into the sky like an eagle chasing its prey

Mario

$LFMD This is so undervalued. Market cap now 50% of annual revenue. Screaming buy right now.

Jonathan

$LFMD less and less people on the site or app every month.  company burning cash like mad when they stopped advertising.  they have the infrastructure all ready.  yet company still isnt profitable.  gj.

jerry del guercio

$LFMD gj justin.  Basically taking your stock almost into reverse split territory.  then bye bye company.

$LFMD people might actually save money on food and grocery bill paying the monthly cost for weight loss drugs. 

This might be one of the greatest marketing campaigns or ideas for LifeMD. High Inflation? Don’t fret, get Ozempic!

$LFMD I can’t believe this is almost in the 1s again…selling this above $5 was one of the best investment decisions I’ve ever made

Love

$LFMD  A lot of big investors and firms bought LFMD at a much higher price than the current price.  And many also ended up exiting for a loss. Thanks for the info though.

Feed

News

Sentiment

Earnings

Fundamentals

Info

LFMD LifeMD Inc

Fundamentals

Latest LFMD News